MedPath

Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone in Young Women With Polycystic Ovary Syndrome

Not Applicable
Conditions
Anti-Mullerian Hormone Deficiency
Polycystic Ovary Syndrome
Female Infertility Endocrine
Interventions
Other: Aerobic exercise training program
Other: Nutritional management
Other: Structured yoga therapy program
Other: Combined yoga and aerobic training program
Registration Number
NCT04335227
Lead Sponsor
Maharishi Markendeswar University (Deemed to be University)
Brief Summary

Weight loss and lifestyle modifications are much required in women with Polycystic ovarian syndrome (PCOS). Yoga has gained great importance as an alternate medicine in recent years which is helpful in lifestyle modifications. Weight loss can be achieved by regular aerobic activity. In recent years, excessive production of anti-mullerian hormone (AMH) has been considered as the etiology of PCOS. AMH is also emerging as a diagnostic and screening tool for PCOS. Effect of yoga therapy on adolescent girls have proved to be effective. But, researches on young women undergoing yoga therapy and combined effect of aerobic exercise and yoga therapy are still lacking. Hence, the investigators aimed t o establish the benefits of yoga therapy and aerobic exercise on Anti-Mullerian Hormone and other biochemical markers in young women with polycystic ovary syndrome.

Detailed Description

A total of 128 female with PCOS will be recruited by the simple random sampling (random number generator) to participate in randomized, single blind randomized controlled, study. Recruited patients with 128 female with PCOS will be randomly divided into four groups, yoga therapy (YT) group, aerobic exercise (AE) group, combined YT and AE (cYTAE) group and control group. Duration of the intervention will be 60 minutes in one session for 6 days/week for 12 weeks. Thus, each women with PCOS will receive 72 sessions in total, except in control group. Anti-Müllerian hormone (AMH) and other biochemical markers such as, Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Testosterone, Prolactin, Thyroid-stimulating hormone (TSH) Ultrasensitive, Dehydroepiandrosterone sulfate (DHEAS), insulin fasting, glucose fasting, HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) and the lipid profiles which includes, total cholesterol, High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C) and serum triglycerides. In addition to the above biochemical markers, transvaginal ultrasound to estimate antral follicle count (AFC) will be recorded at baseline and at the end of 12-week post-intervention period. Following the 12-week intervention, follow-up of another 12-week will be carried out to determine the retention of treatment effects.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
128
Inclusion Criteria
  • Female in age between 18 and 30 years
  • Female with at least two-thirds of the features listed in the Rotterdam criteria for PCOS were included in the study
  • Oligomenorrhea or amenorrhea (an absence of menstruation for 45 or more days and/or fewer than 9 menses per year)
  • Hyperandrogenism (a score of 8 or higher ( ≥ 8) on the modified Ferriman-Gallwey scale)
  • Polycystic ovaries (presence of more than 12 cysts < 9 mm in diameter in single ovary, usually combined with an ovarian volume > 10 ml
Exclusion Criteria
  • On regular hormonal treatment
  • Oral contraceptives
  • Insulin-sensitizing agents in the previous 6 weeks
  • Smoking in less than 48 hours
  • Alcohol in less than 48 hours
  • History of thyroid abnormalities
  • Practicing regular yoga asanas and pranayama
  • Regular aerobic training program

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Aerobic exercise groupAerobic exercise training programAerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
Control groupNutritional managementNutritional management uniquely prepared by dietitian
Yoga therapy groupStructured yoga therapy programStructured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
Combined yoga therapy and aerobic exercise groupCombined yoga and aerobic training programCombined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
Primary Outcome Measures
NameTimeMethod
Serum Anti-Mullerian hormone ConcentrationChange from Baseline Serum Anti-Mullerian hormone Concentration at 12 weeks

Serum Anti-Mullerian hormone will be determined by blinded lab technician

Secondary Outcome Measures
NameTimeMethod
Serum Luteinizing hormone ConcentrationChange from Baseline Serum Luteinizing hormone Concentration at 12 weeks

Serum Luteinizing hormone will be determined by blinded lab technician

Antral follicle countChange from Baseline Antral follicle count at 12 weeks

Antral follicle count will be determined by blinded gynaecologist

Concentration of Lipid profiles in serumChange from Baseline Concentration of Lipid profiles in serum at 12 weeks

Serum total cholesterol, Serum High-density lipoprotein cholesterol, Serum Low-density lipoprotein cholesterol and serum triglycerides

Serum Glucose fasting ConcentrationChange from Baseline Serum Glucose fasting Concentration at 12 weeks

Serum Glucose fasting will be determined by blinded lab technician

Homeostatic Model Assessment for Insulin ResistanceChange from Baseline Homeostatic Model Assessment for Insulin Resistance at 12 weeks

Homeostatic Model Assessment for Insulin Resistance will be determined by blinded lab technician

Serum Follicle-stimulating hormone ConcentrationChange from Baseline Serum Follicle-stimulating hormone Concentration at 12 weeks

Serum Follicle-stimulating hormone will be determined by blinded lab technician

Serum Testosterone ConcentrationChange from Baseline Serum Testosterone Concentration at 12 weeks

Serum Testosterone will be determined by blinded lab technician

Serum Prolactin ConcentrationChange from Baseline Serum Prolactin Concentration at 12 weeks

Serum Prolactin will be determined by blinded lab technician

Serum Thyroid-stimulating hormone ConcentrationChange from Baseline Serum Thyroid-stimulating hormone Concentration at 12 weeks

Serum Thyroid-stimulating hormone will be determined by blinded lab technician

Serum Dehydroepiandrosterone sulfate ConcentrationChange from Baseline Serum Dehydroepiandrosterone sulfate Concentration at 12 weeks

Serum Dehydroepiandrosterone sulfate will be determined by blinded lab technician

Serum Insulin fasting ConcentrationChange from Baseline Serum Insulin fasting Concentration at 12 weeks

Serum Insulin fasting will be determined by blinded lab technician

Trial Locations

Locations (2)

Maharishi Markandeshwar Hospital, Mullana

🇮🇳

Ambala, Haryana, India

Maharishi Markandeshwar Medical College & Hospital, Kumarhatti

🇮🇳

Solan, Himachal Pradesh, India

© Copyright 2025. All Rights Reserved by MedPath